[Federal Register Volume 73, Number 207 (Friday, October 24, 2008)]
[Rules and Regulations]
[Pages 63361-63362]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-25471]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 210 and 211

[Docket No. FDA-2007-N-0379] (formerly Docket No. 2007N-0280)


Amendments to the Current Good Manufacturing Practice Regulations 
for Finished Pharmaceuticals; Final Rule; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a final 
rule that appeared in the Federal Register of Monday, September 8, 2008 
(73 FR 51919). The final rule was published with an inadvertent error 
in the ``Analysis of Impacts'' section. This document corrects that 
error.

FOR FURTHER INFORMATION CONTACT: Diane Sullivan, Office of Policy (HF-
26), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-11, 
Rockville, MD 20857, 301-827-7069, e-mail: [email protected].

SUPPLEMENTARY INFORMATION: In FR Doc. E8-20709, appearing on page 51919 
in the Federal Register of Monday, September 8, 2008, the following 
correction is made:
    1. On page 51931, in the first column, under ``IV. Analysis of 
Impacts,'' in the first full paragraph, the sentence ``The agency 
believes that this final rule is not a significant regulatory action as 
defined by the Executive order, because the rule either clarifies the 
agency's longstanding interpretation of, or increases latitude for 
manufacturers in complying with, existing CGMP requirements'' is 
corrected to read ``The agency certifies that this final rule is not a 
significant regulatory action as defined by the Executive order, 
because the rule either clarifies the agency's longstanding 
interpretation of, or increases latitude for manufacturers in complying 
with, existing CGMP requirements.''


[[Page 63362]]


    Dated: October 16, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-25471 Filed 10-23-08; 8:45 am]
BILLING CODE 4160-01-S